{"analyses":[{"ciLowerLimit":"0.304","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.099","estimateComment":"The HR and 95% CI were estimated from a stratified Cox proportional hazards model.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.091","pValueComment":"The 2-sided nominal p-value was calculated based on a stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.578","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% confidence interval were not reached due to insufficient number of events at the time of data cutoff.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median event rate was not reached, and the upper limit of the 95% confidence interval could not be estimated due to insufficient number of events beyond the median at time of data cutoff.","groupId":"OG001","lowerLimit":"33.54","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"description":"Physical Functioning was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) Physical Function (PF) scale consisting of 5 items to measure the impact of the disease and its treatment on a participant's ability to perform everyday physical activities, calculated from responses to the five items, each scored on a 4 point scale (1 = not at all to 4 = very much). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing better functioning. TTW of PF was defined as the time from randomization to the earliest date of the first sustained worsening from baseline, with a decline in the meaningful within-person change (MWPC) threshold of -13.33 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A - Pirtobrutinib"},{"description":"Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD).","id":"OG001","title":"Arm B - Bendamustine Plus Rituximab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization up to 37 months","title":"Arm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30","type":"SECONDARY","unitOfMeasure":"Months"}